The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ligelizumab for Chronic Spontaneous Urticaria
Open accessAbstract
BACKGROUNDIn the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control.Ligelizumab is a nextgeneration high-affinity humanized monoclonal anti-IgE antibody.Data are limited regarding the dose-response relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H 1 -antihistamines at approved or increased doses, alone or in combination with H 2 -antihistamines or leukotriene-receptor antagonists. METHODSIn a phase 2b dose-finding trial, we randomly assigned patients to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab.Disease symptoms of hives, itch, and angioedema were monitored by means of weekly activity scores.The main objective was to determine a dose-response relationship for the complete control of hives (indicated by a weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating greater severity); the primary end point of this response was assessed at week 12. Complete symptom control was indicated by a weekly urticaria activity score of 0 (on a scale from 0 to 42, with higher scores indicating greater severity).Safety was analyzed throughout the trial. RESULTSA total of 382 patients underwent randomization.At week 12, a total of 30%, 51%, and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of hives, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group.A dose-response relationship was established.At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group.In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. CONCLUSIONSA higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo.(Funded by Novartis Pharma; ClinicalTrials.govnumber, NCT02477332.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE ‐ CSU
Maurer, M., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J. ‐., et al. (2017) · Allergy · doi:10.1111/all.13209 · Cited by 383
Self-citation
Cited by
Kolkhir, P., Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., & Maurer, M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00389-z · Cited by 382
Self-citationThe role of allergen‐specific IgE, IgG and IgA in allergic disease
Shamji, M. H., Valenta, R., Jardetzky, T., Verhasselt, V., Durham, S. R., Würtzen, P. A., & van Neerven, R. J. J. (2021) · Allergy · doi:10.1111/all.14908 · Cited by 336
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
The ingenious mast cell: contemporary insights into mast cell behavior and function
Dahlin, J. S., Maurer, M., Metcalfe, D. D., Pejler, G., Sagi‐Eisenberg, R., & Nilsson, G. (2022) · Allergy · doi:10.1111/all.14881 · Cited by 147
Self-citationNew and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Metadata
- Authors
- Maurer, M., Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hébert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., Staubach, P., Wedi, B., Löffler, J., Barve, A., Kobayashi, K., Hua, E., Severin, T., & Janocha, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-03
- Volume
- 381
- Issue
- 14
- Pages
- 1321-1332
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2978592627
- Cited by
- 252
- References
- 1
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ligelizumab for Chronic Spontaneous Urticaria. https://app.cochat.ai/papers/10.1056/nejmoa1900408
- The paper
- Maurer, M., Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hébert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., . . . Janocha, R. (2019). Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1900408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.